Galmed Pharmaceuticals Ltd.
NASDAQ: GLMD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Allen Baharaff
- Employees
- 5
- Headquarters
- Ramat Gan, Israel
- IPO year
- 2014
- Market cap
- $3.2M
- Website
- https://galmedpharma.com
Loading GLMD…
Loading profile data…Frequently asked questions about GLMD
What does Galmed Pharmaceuticals Ltd. (GLMD) do?
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight...
Where does GLMD trade?
Galmed Pharmaceuticals Ltd. (GLMD) trades on the NASDAQ.
What sector is GLMD in?
Galmed Pharmaceuticals Ltd. (GLMD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Galmed Pharmaceuticals Ltd.?
Allen Baharaff is the chief executive officer of Galmed Pharmaceuticals Ltd. (GLMD).
Where is Galmed Pharmaceuticals Ltd. headquartered?
Galmed Pharmaceuticals Ltd. is headquartered in Israel.
Does GLMD pay a dividend?
Galmed Pharmaceuticals Ltd. (GLMD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLMD go public?
Galmed Pharmaceuticals Ltd. (GLMD) completed its initial public offering in 2014.